Dr. Mark Kiel is the founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. After spending 15 years preparing for a life of academic research, Mark became convinced that revolutionary change in genomics was more likely to emerge from industry.

In 2014, he founded Genomenon, an AI-driven genomics company addressing the challenge of connecting researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cancer.

Prior to starting Genomenon, Mark completed his MD PhD and residency in Clinical Pathology at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. While at Michigan, he completed a fellowship in Molecular Diagnostics and devised the informatics framework for clinical next-generation sequencing in the Molecular Diagnostics Laboratory.

During his doctoral studies, he made ground-breaking contributions to the study of hematopoietic stem cells, for which he was awarded the Weintraub International Graduate Student Award and the ProQuest Distinguished Dissertation Award. While a postdoctoral researcher, he made significant contributions to the field of Hematopathology, including genomic profiling of lymphoid malignancies, for which he was awarded the Benjamin Castleman Award.